In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cytokine PharmaSciences Inc.

Division of Ferring Pharmaceuticals AS

Latest From Cytokine PharmaSciences Inc.

Deals Shaping The Medical Industry (12/2011)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device

Altering The Insulin Resistance System

With the US deeply mired in an obesity epidemic, a growing aging population throughout the developed world, and rising rates of obesity, the market for therapeutic agents for metabolic disorders and especially type 2 diabetes will continue to grow. Little wonder that many emerging companies are pursuing innovative metabolic, obesity, and type 2 diabetes programs to supplement those of Big Pharma. We profile four of them in this issue: Catabasis Pharmaceuticals, Limerick BioPharma, Marcadia Biotech and Rhythm Pharmaceuticals.

Pfizer strikes Chinese alliance for Depo-Provera

Pfizer has entered into an alliance with BMP Sunstone for the commercialisation of its synthetic progesterone product Depo-Provera (medroxyprogesterone acetate) in China.

Gynecology & Urology Neurology

Controlled Therapeutics receives grant from Scottish government

Controlled Therapeutics (Scotland) has received a £930,000 grant from the Scottish Executive's regional selective assistance programme, which will go towards creating 23 new positions at its East Kilbride facility. The company, a subsidiary of the US firm Cytokine PharmaSciences, conducts research and manufacturing there, and Cytokine Pharmasciences' president and CEO Dennis Wilson said the company was investing $6 million in Scotland. Patent protection on its Hydrogel technology, which was acquired from the University of Strathclyde, runs out in 2012, but it plans to develop both its existing polymer technology and new technologies based on linear polymers.

Companies Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Site Specific
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Cytokine Networks Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Ferring Pharmaceuticals AS
  • Senior Management
  • Dennis Willson, Pres. & CEO
    John A Bond, CFO
    Vidal F de la Cruz, PhD, VP, Bus. Dev.
    Barbara L Powers, PhD, VP, Clinical Dev.
  • Contact Info
  • Cytokine PharmaSciences Inc.
    Phone: (610) 687-1776
    Walnut Hill Plaza, 150 South Warner Rd.
    Ste. 420
    King of Prussia, PA 19406